SUMMARY
INTRODUCTION
The great majority of patients with severe asthma are step 4 asthmatics, meaning that their asthma can be controlled with high doses of inhaled corticosteroids and long acting β2 agonists. However, the remaining patients with severe asthma are candidates for step 5 treatment, as their condition cannot be controlled with step 4 medications (1-3). Since these patients have severe asthma, require many medications, frequently visit emergency rooms, and are often hospitalized, this condition places a significant burden on both the patients and the health care system (4, 5) .
Around 5-10% of patients with asthma have severe asthma. IgE-mediated immune mechanisms are thought to play a role in over 50% of these patients (6) . Omalizumab is a recombinant humanized monoclonal antibody that complexes with free IgE, thereby preventing it from adhering to specific receptors on mast cells and basophils (FcRI). Omalizumab therefore acts as a potent antiinflammatory agent in patients with severe perennial allergic asthma (7) . Three studies with follow-up periods of 0.5, 4 and 7 years found that omalizumab effectively decreases asthma exacerbations, lowers steroid doses, and imposes better asthma control (8) (9) (10) . Four randomized controlled studies of omalizumab also showed that it decreases asthmarelated symptoms, reduces corticosteroid use, and improves quality of life (11) (12) (13) (14) .
In recent years, case reports and a Spanish multicenter registry study showed that omalizumab is also effective in non-allergic asthma (15) . Thereafter, research efforts turned to assessing the usefulness of omalizumab in patients with non-allergic asthma.
However, at present, the guidelines state that when non-allergic asthma is even unresponsive to macrolide or tiotropium medications and another diagnosis cannot be made, oral corticosteroid or anticytokine treatments should be administered (16, 17) . However, the long-term outcomes of patients with non-allergic step 5 asthma who do not accept treatment with continuous oral steroids remain unclear.
The present cohort study was performed to determine the outcomes over a 5 year follow-up period of patients whose severe persistent asthma was not controlled by step 4 treatment (ICS and LABA). If they had allergic asthma, omalizumab was added to the treatment. If they had non-allergic asthma, other controllers (but not continuous oral corticosteroid) were added. The two groups were examined for the rates of asthma control, asthma exacerbation, and other asthma variables at several time points over the 5 year follow-up period.
MATERIALS and METHODS

Selection of the Study Cohorts
The study protocol was approved by the local ethical board (no: 1643). The study was performed in the Department of Pulmonology of our university hospital, and the study period was 2006-2014. The study consisted of two groups of patients with severe persistent asthma that was not controlled by step 4 treatment. In all cases, asthma was diagnosed on the basis of GINA (Global Initiative for Asthma) criteria, namely, a clinical history of symptoms compatible with asthma and reversibility of bronchial obstruction, as measured by spirometry and defined as a post bronchodilator change in FEV 1 (forced expiratory volume in one second) of 12% and 200 mL. (18) . The inclusion criteria for the EXALT Study were as follows: all consecutive patients who were > 12 years old and had FEV 1 < 80%, an asthma control test (ACT) < 20, at least two exacerbations that required treatment with systemic steroids in the 12 months before inclusion in the study, uncontrolled severe persistent asthma despite having regularly taken high-dose ICS and LABA, and smoking < 10 pack/year. The exclusion criteria for the EXALT Study were as follows: presence of any hematological, malignant, coronary, renal, hepatic, endocrinological, or gastrointestinal pathology that could affect the results, BMI > 35, steroid resistance, continuous oral steroid use, presence of mycoplasma or chlamydia saprophytes, or nocturnal, premenstrual, or brittle asthma. In total, 24 consecutive patients satisfied these eligibility criteria (n= 24). Of these, 17 were included in the EXALT Study because their total serum IgE levels were 30-700 IU/mL, they had perennial allergy (as established by a skin prick test and/or the presence of specific IgE), and they were suitable for omalizumab treatment (as indicated by the dose table, which was based on body weight and IgE levels). All patients enrolled in the EXALT Study started receiving omalizumab in addition to highdose ICS and LABA. After the EXALT Study was completed in September 2008, these severe allergic asthma patients continued to receive omalizumab, high-dose ICS, and LABA, and were followed up for at least another 5 years.
The non-allergic group, was selected by a retrospective chart review that identified all consecutive patients with severe persistent non-allergic asthma that was initially not controlled by step 4 treatment and was then treated with step 5 therapy [combined high-dose inhaled steroid therapy and continuous oral corticosteroids: median 8 mg metyl prednisolone (minimum; 4 mg and maximum 12 mg)] for at least 5 years. The patients who met all of the eligibility criteria that were used to select the allergic asthma group (except positivity for the skin prick test) were enrolled in the present study. These patients were followed up between 2006 and 2014 in the outpatient clinic of the Department of Pulmonology.
Non adherence, inadequate inhalation technique, nonstable comorbidities or persistent risk factors that interfere with the asthma control were also exclusion criterias during five years for all patients.
Primary Outcomes of Treatment
For both groups, the following information was gathered at several time points after the patients first presented with severe persistent asthma that was not controlled by step 4 therapy: (i) ACTs and FEV 1 at the first presentation and 16 weeks, and at the end of 1, 2, and 5 years after presentation; (ii) number of exacerbations requiring at least 3 days of steroid treatment in the 12 months before step 5 therapy started, and the 1 st , 2 nd , and 5 th year after step 5 commencement; (iii) amount of inhaled corticosteroid in the 12 months before step 5 therapy started, and 1 and 5 years after step 5 treatment started.
Statistical Analysis
The groups were compared in terms of the primary outcomes by using the SPSS 20.0 statistics program. Changes from the initial time point over time were assessed by student-t test. The two groups were compared by using the Mann-Whitney U test.
RESULTS
The allergic asthma group consisted of 17 patients (13 females and 4 males; average age, 48.3 ± 16.4 years). They had been followed up for 5.5 (range, 5.5-7) years. The non-allergic asthma group consisted of 16 patients (15 females and 1 male; average age, 52.3 ± 13.2 years). They had been followed up for 5.5 (range, 5.5-20) years. Table 1 indicates how each group changed over time in terms of number of exacerbations, FEV 1 , and ACT after step 5 therapy started. The table also shows how the two groups compared in terms of these variables at each followup time point. They have similar baseline ACTs, FEV 1 , and exacerbation rates (p> 0.05).
The mean exacerbation rate of two groups during 5 years is demonstrated in Figure 1 .
The allergic and non-allergic groups had, on average, 2.57 and 2.38 exacerbations during the 12 months before the patients switched to step 5 therapy, respectively. By the end of the 1 st and 2 nd years, the exacerbations in both groups had dropped significantly compared to baseline (all p< 0.001). This drop continued to be observed in the allergic group at the end of the 5th year (0.59, p< 0.001 compared to baseline): this represented a 77.1% drop relative to baseline. By contrast, the number of exacerbations in the non-allergic group rose to 3.3 at the end of the 5 th year (3.3, p< 0.001): this represented a 39.6% increase relative to baseline. Although the two groups did not differ significantly in terms of baseline exacerbation rates, the allergic group had significantly fewer exacerbations than the non-allergic group at the end of the 1 st , 2 nd , and 5 th years (p< 0.02, p< 0.03, and p< 0.02, respectively). However, it should be noted that 8 of the 17 allergic group patients (47%) still had one or two exacerbations in the 5 th year.
The baseline FEV 1 levels of the non-allergic and allergic groups were 1.68 ± 0.5 L and 1.34 ± 0.5 L, respectively. The non-allergic group exhibited a significant increase in FEV 1 at the 1 year time point only (p< 0.05), while the allergic group showed significant increases at both the 16 th week and 1 st year time points (p< 0.01 and p< 0.01, respectively).
At the 5 th year, the non-allergic group showed an 11% increase in FEV 1 , while the allergic group showed a 4.3% decrease in FEV 1 relative to baseline; however, these changes relative to baseline were not statistically significant. While the 5 th year average FEV 1 was increased at 1.50 ± 0.5 L in the omalizumab group, this was not statistically significant. The two groups did not differ significantly at any time point in terms of FEV 1 (p> 0.05). Despite the improvement seen in the allergic group, however, only 2 of these 17 (11.7%) patients reached FEV 1 greater than 80% after 5 years of omalizumab therapy. Mean FEV 1 levels of allergic and non allergic groups during 5 year period are seen on Figure 2 .
The baseline ACTs of the non-allergic and allergic groups were 14.6 ± 3.9 and 17.7 ± 1.4, respectfully. In both groups, the ACTs at all subsequent time points were significantly higher than at baseline (all p< 0.01). The allergic group had 13.5%, 10.16%, and 11.6% higher ACTs than the non-allergic group at the 16 th week (p< 0.01), 1 st year (p< 0.03), and 2 nd year (p< 0.01), respectively. The allergic group also had a 3.1% increase in ACT at the 5 th year compared to the non-allergic group, but this difference did not achieve statistical significance (p> 0.05). Only 3 patients (17.6%) in allergic group and 2 patients (12.5%) in non allergic group had ACT below 20 at the end of the 5 th year. Mean ACT levels of allergic and non allergic groups during 5 year period are seen on Figure 3 .
The inhaled steroid dosage of the non-allergic group did not change over time relative to baseline (p> 0.05).
By contrast, the inhaled steroid dosage of the allergic group dropped after starting omalizumab therapy: compared to the inhaled steroid dosage in the 12 months preceding the start of step 5 therapy, a drop of 65% was observed at the 5 th year. The allergic group also exhibited significantly lower inhaled steroid dosages than the non-allergic group at the 1 st and 5 th year (p< 0.002 and p< 0.002, respectively), even though the two groups did not differ significantly at baseline in terms of this variable. Despite the improvement seen in the allergic group, however, 6 of these 17 (35%) patients still required high doses of inhaled steroid after 5 years of omalizumab therapy. 
DISCUSSION
Although we have some limitations of the study regarding the small number of patients in the study groups and the retrospective analysis of the non allergic groups, we showed that the allergic group, who received omalizumab, generally performed quite well over the 5 year treatment. Thus, compared to the 12 months before step 5 therapy started, the exacerbations in the allergic group had dropped by 77.1% by the end of the fifth year. However as an unexpected result of the study, 47% of the patients presented at least one excerbation in the fifth year. The allergic group also exhibited a rise in ACTs by 31% at the fifth year, although this did not achieve statistical significance. Only %17.6 had ACT below 20. The contrast between the exacerbation rate end the results of the ACT in the fifth year is attributed to the methodology is one of the limitation of the study.
As ACT results reflect only the last month and were taken at the end of the each treatment year in our study, if the exacerbation was in an other time of the year patient might be better after some months. The problem may be the drop in the dosage of inhaled steroid as the allergic group showed a 65% drop in inhaled steroid dosage at the fifth year.
Several studies showed that omalizumab is an effective and safe treatment for severe allergic asthma. In the German registry real life study, omalizumab treatment decreased exacerbations by 75% at the 16 th week (19) . Real-life data from 14 countries
showed that 2 year of omalizumab treatment significantly improved the exacerbation rate, by 67.3% (20) . The exacerbation rate decreased 70% in the Southeastern mediterannean real life study after 4 years (21). Our present study showed that omalizumab treatment decreased exacerbations in the allergic asthma group by 77.1% at the fifth year.
Bousquet et al. pooled the data of seven studies, they found that omalizumab decreased asthma exacerbations in patients with severe allergic asthma by 38% (22) . Hanania et al study in 850 patients, showed that omalizumab treatment decreased 25% more exacerbations then plasebo after 48 weeks (23) . The systematic review of Norman et al. also showed that in patients with allergic asthma, omalizumab decreased the exacerbations (24) . A systematic metaanalysis evaluating the effectiveness of omalizumab versus placebo in 3429 patients with moderatesevere persistent allergic asthma found that omalizumab treatment (1883 patients) significantly improved asthma exacerbations, steroid dose requirement, and asthma symptom scores (25) .
The EXELS study published in 2012 showed that omalizumab treatment significantly improved ACTs in allergic asthma patients at the sixth month and that this remained evident at the second year of follow-up (26) . They showed that at the end of the second year 59% of patient had ACT ≥ 20. This rate was 82.3 at the end of the fifth year in our study. Ozgur ES et al from Turkey showed that long-term therapy with omalizumab for up to 3 years significantly increased ACT (27) . Similarly, the present study showed that omalizumab significantly improved ACTs at the 16 th week (13.5% improvement relative to baseline) and that this effect persisted at the first (10.6%), second (11.9%), and fifth (3.1%) year.
With regard to dosage of inhaled corticosteroids, three studies in 2001 found that omalizumab decreased the need for inhaled corticosteroids (28) (29) (30) . A Spanish study by Vennera et al. also showed that after a 2 year follow-up, the required steroid dosages of patients with severe allergic asthma decreased after omalizumab therapy (31) . Similarly, the present study showed that omalizumab significantly decreased the inhaled steroid dosage of the allergic asthma group by 65% at the fifth year.
While the 5 year omalizumab treatment did improve most asthma variables in the patients with allergic asthma, 47% still had at least one exacerbation in the fifth year. Moreover, 35% still required high doses of inhaled steroid therapy, and 88% had FEV 1 below 80% at the fifth year. We believe that those problems still must be questionned in regard to need of other therapies.
Regarding the non-allergic group in the present study, the fact that exacerbations rose by 39.6% relative to baseline at the fifth year contrasts with the fact that the same group consistently exhibited significant increases in ACT, even at the fifth year. This may be attributed to the good adherence of these patients to step 5 therapy due to their routine follow-up in a university hospital outpatient clinic and their expectation of receiving a new drug for asthma. However, this is speculation at present: we did not examine whether non-drug factors such as treatment adherence could be responsible for the increased ACT in this group (1). The Spanish registry study of Llana et al. showed that during a 2 year period, omalizumab also significantly improved the ACTs of non-allergic asthma patients at the 1 st and 2 nd years. However, it had no effect on FEV 1 and exacerbations (15) . In the present study, the step 5-treated nonallergic group, who were not treated with omalizumab, also exhibited significantly increased ACTs at all time points. However, unlike the Spanish study, the non-allergic group exhibited significant decreases in exacerbation rates at all time points as well. With regard to FEV 1 levels, there was a small increase in this variable in the omalizumab group (11%) at the end of the fifth year and a small decrease (4.3%) in the non-allergic group. These changes relative to baseline did not achieve statistical significance.
CONCLUSION
The present study showed that in suitable patients whose asthma is difficult to control, omalizumab can effectively improve asthma control and prevent exacerbations. However, many of the omalizumabtreated allergic asthma patients still exhibited exacerbations. This was also observed for the step 5-treated non-allergic patients. Especially, non allergic group of patients demonstrated a need for new medications paves the way for improving the treatment of non-allergic asthma patients.
